AcuityMD Launches ‘Pipeline’ to Enable MedTech Commercial Teams to Forecast with Accuracy and Improve Sales Planning

AcuityMD, provider of a novel commercial platform for medical technology (MedTech) companies, announced the launch of Pipeline, a new module that enables sales representatives to execute on prospects throughout the sales lifecycle, track progress, forecast accurately, and ultimately improve business planning to grow revenue.

AcuityMD’s Pipeline solution addresses the challenges of the complex MedTech sales lifecycle. Healthcare professionals (HCPs) use MedTech products in vastly different ways depending on various factors, such as product type, surgical procedure, clinical preference, patient characteristics, among others. This makes managing opportunities and predicting ongoing product usage extremely complicated since teams often lack solid data to inform sales forecasts and revenue impact for both the remaining and next fiscal years.

“Pipeline is a game-changer as many MedTech companies struggle to manage the unique complexities of selling medical devices without industry-specific technology,” said Michael Monovoukas, co-founder and CEO of AcuityMD. “Traditional CRMs aren’t natively embedded with customer data, and generic software fails to accommodate the nuances of customer management in the MedTech space. As a result, running a sales process across complex customer profiles is often cumbersome, time consuming, and inaccurate, putting business goals at risk and making it difficult to plan.”

AcuityMD customer, Anika Therapeutics, Inc., a global joint preservation MedTech company, sought a single solution to manage customer opportunities and achieve their vision of a centralized sales process. They expanded their partnership with AcuityMD as an early adopter of AcuityMD Pipeline, which brings opportunity capture and management to the unified platform. In 2019, Anika’s sales team used AcuityMD’s Targeting platform to identify and prioritize new prospects.

“With Acuity’s Targeting solution, we were able to surface over 500 relevant surgeons,” said Rob Delp, vice president, U.S. sales, at Anika. “Now that we’ve identified the prospects, we’re leveraging Pipeline to execute on these opportunities faster, forecast more accurately, and deliver on our sales projections by mapping out an end-to-end view of sales cycles in a single source of truth.”

Benefits of AcuityMD Pipeline:

  • Built for MedTech’s unique data and workflows – Pipeline maps to MedTech’s specific data and sales structure, allowing teams to forecast and meet quota more accurately.
  • Unified end-end platform – Pipeline enables sales representatives to identify opportunities, fill their pipeline, and move prospects through the sales cycle in one unified system, making it easier to continuously monitor progress towards quota and close any gaps with fresh opportunities.
  • Fully integrated with MedTech data – Pipeline gives teams ready-to-use information relevant to each opportunity. In addition to saving time on data entry and maintenance, teams have confidence that their forecasts are reliable.
  • Built for Desktop and Mobile – Pipeline is also built with full functional depth on the AcuityMD Mobile App, making it even easier to update and track on the go.

Pipeline is now generally available and part of the AcuityMD platform.

 

SourceAcuityMD
Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.
"Exact Sciences is looking forward to presenting new evidence at SABCS that adds important perspectives to treating breast cancer patients and showing that some patients may be able to de-escalate treatments and still have positive outcomes," said Dr. Rick Baehner, Chief Medical Officer, Precision Oncology, Exact Sciences. "Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients. We are pleased to see authorities expanding access to this test as we continue to develop key evidence in collaboration with some of the world's most prestigious, breast cancer-focused organizations."
Clozapine has been established as the most effective antipsychotic medication for treatment-resistant schizophrenia. However, it is significantly underutilized mainly due to the risk of developing agranulocytosis and the need to frequently monitor the absolute neutrophil count (ANC).
Dagi-Ben Noon, CEO of Inspira Technologies, reflects on the partnership's significance: "By Integrating our technology to oxygenate blood directly with Ennocure's infection prevention solutions, we are focusing on potentially improving patient outcomes in ICUs and paving the way for safer, more effective life-support treatments. This collaboration is expected to accelerate the development and broaden the implementation of our advanced technology."
The findings suggest that the novel, non-invasive genomic test can help physicians guide next steps for these patients, enabling them to potentially avoid unnecessary invasive procedures or accelerate time to appropriate treatment.

By using this website you agree to accept Medical Device News Magazine Privacy Policy